-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
InnoModels Biotechnology: What are the features of PDC high-throughput in vitro drug efficacy platform?
Author:
InnoModels
Release time:
2024-05-27
With the rapid development of medical science and technology, the R&D process of new drugs is increasingly demanding in terms of efficiency, accuracy and cost. Against this backdrop, the InnoModels Biotechnology PDC platform has emerged to revolutionize the field of new drug discovery and development with its unique technological advantages. In this paper, we will introduce the features of the InnoModels Biotechnology PDC high-throughput in vitro drug efficacy platform in detail, in order to reveal its important value in drug research.
1、Highly consistent primary cell support
Using the digestion products of the PDX model, the PDC high-throughput in vitro drug efficacy platform of InnoModels Biotechnology has successfully obtained highly consistent primary cells with patients. These cells not only have complex cell subpopulations and biological characteristics, but are also able to more closely mimic drug actions and responses in clinical situations. This provides researchers with valuable experimental materials, making the results of drug development more meaningful.
2、Efficient prediction of drug clinical efficacy
The platform can not only be used for the screening of test drugs and models, but also can predict the clinical effectiveness of drugs. By comparing the efficacy response of the subject drug with that of a standard drug (e.g., a drug with a similar mechanism of action or a standardized therapeutic drug), the researcher is able to more accurately assess the clinical value of the drug. This predictive ability helps to reduce blindness in the drug development process and improve the success rate.
3、Significant Experimental Efficiency and Cost Advantages
Compared with the traditional in vivo experimental platform, InnoModels' PDC high-throughput in vitro drug efficacy platform has a significant experimental cycle advantage. The in vitro experimental platform can shorten the experimental cycle by more than three times, and at the same time, the flux of the tested drugs can be increased by more than five times. What's more, the cost of the platform is only a fraction of that of in vivo experiments. This enables researchers to accomplish more drug screening and efficacy testing within limited time and budget, improving R&D efficiency.

4、Multi-parameter assay and multi-cell type support
PDC technology allows researchers to simultaneously assess multiple cell phenotypic parameters, such as cell proliferation, cell cycle, apoptosis, etc., providing a more comprehensive understanding of drug effects. In addition, the technology supports the application of multiple cell types, including tumor cells, primary cells, etc., for drug research in different disease areas. This flexibility allows the InnoModels Biotechnology PDC high-throughput in vitro drug efficacy platform to meet a wider range of research needs.
5、High-throughput Screening and Customized Service
The platform is equipped with high-throughput screening capabilities, enabling rapid screening of a large number of drugs in a short period of time. This not only improves research efficiency, but also provides strong support for efficient drug discovery. In addition, InnoModels Biotechnology also provides customized services to tailor the experimental protocols according to the specific needs of the researcher, ensuring the accuracy and reliability of the experimental results.
Summary:
With its highly consistent primary cell support, efficient prediction of drug clinical effectiveness, significant experimental efficiency and cost advantages, multi-parameter assay and multi-cell type support, as well as high-throughput screening and customized services, the PDC high-throughput in vitro efficacy platform from InnoModels Biotechnology has revolutionized the field of new drug discovery and development. The emergence of this platform will strongly promote the process of new drug R&D, accelerate the pace of drug launch, and make important contributions to human health.
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd